Invivyd, Inc. Files 8-K on Financials and Other Events

TL;DR

Invivyd dropped an 8-K covering financials and other key events.

AI Summary

Invivyd, Inc. filed an 8-K on February 3, 2025, reporting on its Results of Operations and Financial Condition, Other Events, and Financial Statements and Exhibits. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.

Why It Matters

This filing provides an update on Invivyd's financial condition and any significant events that occurred, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This is a routine filing providing information on financial condition and other events, not indicating immediate significant risk.

Key Players & Entities

• Invivyd, Inc. (company) — Registrant
• Adagio Therapeutics, Inc. (company) — Former Company Name
• February 3, 2025 (date) — Date of Report
• Waltham, MA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar

Filing Documents

• ivvd-20250203.htm (8-K) — 59KB
• ivvd-ex99_1.htm (EX-99.1) — 33KB
• ivvd-ex99_2.htm (EX-99.2) — 45KB
• img59752938_0.jpg (GRAPHIC) — 84KB
• img60676459_0.jpg (GRAPHIC) — 84KB
• img60676459_1.jpg (GRAPHIC) — 853KB
• 0000950170-25-012018.txt ( ) — 1683KB
• ivvd-20250203.xsd (EX-101.SCH) — 31KB
• ivvd-20250203_htm.xml (XML) — 5KB

02

Item 2.02. Results of Operations and Financial Condition. On February 3, 2025, Invivyd, Inc. (the "Company") issued a press release entitled "Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability" (the "Press Release"), which included the Company's estimated fourth quarter 2024 PEMGARDA (pemivibart) net product revenue, fourth quarter 2024 total operating costs and expenses, and cash and cash equivalents as of December 31, 2024. The amounts included in the Press Release are preliminary and are subject to change upon completion of the Company's financial closing controls and procedures for the quarter and year ended December 31, 2024, and finalization of the Company's financial statements. The preliminary financial data included in the Press Release have been prepared by, and are the responsibility of, the Company's management. These preliminary estimates have not been audited by the Company's independent registered public accounting firm. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2024. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 2.02.

01

Item 8.01. Other Events. On February 3, 2025, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01. On February 3, 2025, the Company issued a press release entitled "Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population." A copy of the press release is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated February 3, 2025 99.2 Press Release, dated February 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: February 3, 2025 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR